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Introduction
A large number of pharmacological compounds are administered 
systemically, however this method of treatment can often offer some 
limitations. Some of the compounds used in therapy can be unstable in 
physiological fluids due to their short half-life or may become unstable 
as a result of modification by endogenous enzymes. Moreover, many 
pharmaceutical drugs are unspecific and when diffuse into healthy 
tissues can cause severe side effects, thus limiting the efficacy of 
treatments. On the contrary, other molecules although specific can have 
limited access to the target sites and consequently large quantities of the 
pharmaceutical have to be used in order to achieve therapeutic effects.
For all of the above reasons, many efforts are made to develop new 
drug delivery systems capable of improving the delivery of therapeutic 
agents to target tissues. [1-5]. Engineered peptides [6,7], nanoparticles 
[8,9], and polymers [10,11] have all been proposed as potential carriers 
for bioactive compounds. However, these delivery systems may have 
different factors limiting their application including the reduced 
amount and/or dimensions of molecules that can be delivered, the 
restricted carrying capacity, and the possibility of altering the drugs 
release [1, 12].
In the last years, cell-based carriers including erythrocytes, 
leukocytes, platelets, hepatocytes, and fibroblasts have been suggested 
as possible vehicles for therapeutic compounds [13]. Cellular carriers 
constitute attractive possibilities especially to deliver those compounds, 
which are expensive to synthesize, have reduced half-lives, or are 
rapidly inactivated in vivo following administration [14]. In particular, 
the use of erythrocytes has gained remarkable interest and several types 
of erythrocytes have been engineered to deliver various therapeutic 
agents.  Some of these systems include erythrocytes from mice, rats, 
rabbits, chicken, cattle, pigs, dogs, sheep, goats, and monkeys. There 
are several advantages to use red blood cells as vehicles for therapeutic 
compounds. In fact, because the erythrocytes can be endogenous, 
the possibility of acquiring a severe immunologic reaction is greatly 
reduced. [15,16]. Moreover, erythrocytes provide an intracellular 
environment, which can protect the loaded drug from degradation 
[16,17]. Consequently, the erythrocytes used as cell-based carriers 
can improve the pharmacokinetics and pharmacodynamics of drugs 
used in treatments [15], and at the same time can reduce potential side 
effects. Furthermore, the relatively simple but stable metabolic system 
of the red blood cells offers also an additional advantage. Pro-drugs, 
which have to be metabolically converted into active compounds, can 
be activated by endogenous enzymes following their encapsulation 
in the erythrocytes.  Therefore, when the activated compounds reach 
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Abstract
The pharmacological properties of many drugs can be improved by drug delivery systems able to drive therapeutic 
agents to target regions. The use of carriers, in fact, may reduce possible cytotoxic effects of drugs and increase 
their bioavailability at the site of action, thus improving the efficacy and the safety of treatments. Therefore, we have 
developed an erythrocyte-based drug delivery system (erythro-magneto-HA virosome), which has the potential to be 
magnetically guided to specific sites and to fuse with target cells. These engineered erythrocytes have demonstrated 
in previous work a very high in vitro capability to release anticancer drugs directly inside target cells. Because the 
erythro-magneto-HA virosomes (EMHVs) proved to be promising carriers, we decided to investigate in more details 
the effectiveness and safety of this erythrocyte-based drug delivery system. 
We evaluated the ability of the EMHVs to be specifically localized in vivo to desired sites by means of an external 
magnetic field and to protect an anticancer drug such as 5-Aza-2’-deoxycytidine from degradation.  Additionally we 
have assessed the ability of the EMHVs to act as bioreactors and to convert the pro-drug 5-Aza-2’-deoxycytidine into 
an active drug. Finally, we have studied the interaction of the EMHVs with the host immune system. 
The pro-drug 5-Aza-2’-deoxycytidine has short half-life when systemically injected and needs to be phosphorylated 
to become an active drug.  We found that when inside the engineered erythrocytes it is protected by degradation 
and is transformed in its active form thus becoming readily available for uptake by the targeted cells. Moreover, we 
have observed that the EMHVs used didn’t cause either a cell-mediated or a humoral immune response in host mice 
having the same haplotype of the donors.
These findings suggest that erythro-magneto-HA virosomes are a safe and useful drug delivery system that may 
offer numerous advantages for several clinical applications.
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the target site, they are readily available for uptake by the cells to be 
treated [18,19]. Because of all of the above, erythrocytes can act as 
either passive carriers or bioreactors that can play an active role in the 
pharmacokinetics of the drug. Furthermore, due to their physiological 
role in nature, erythrocytes have the ability to reach all tissues of the 
body.
In previous work we have explored the potential abilities of red 
blood cells to be cellular carrier and have developed a new drug delivery 
system with the aim of improving the release of therapeutic compounds 
within specific target cells [20]. By encapsulating superparamagnetic 
nanoparticles within erythrocytes and by loading into their membrane 
the viral fusogenic protein hemagglutinin (HA), we have produced 
erythro-magneto-HA virosomes (EMHVs), which have the potential 
to be magnetically concentrated to specific sites and also to fuse with 
target cells. To complete our delivery system we have encapsulated 
the demethylating agent 5-Aza-2’-deoxycytidine (5-Aza-dC) into the 
EMHVs, and have demonstrated that, due to the capacity of this novel 
delivery system to release the compound directly inside the targeted 
cells, very low doses of drug may be sufficient for an effective therapy 
[18]. Our results suggested that this system may reduce cytotoxic 
effects of drugs by increasing its bioavailability at the site of action, thus 
improving its pharmacokinetics. These features make our engineered 
erythrocytes an appealing candidate to be used in the treatment of 
cancer and other diseases that require the delivery of therapeutics to 
specific sites.
For this reason, in the current work we analyzed more details 
the effectiveness of this drug delivery system to better characterize it 
for its use during in vivo applications.  In particular, we studied the 
quality and the amount of the 5-Aza-dC encapsulated in the EMHVs. 
Additionally, we have evaluated the ability of the EMHVs to localize 
to target sites under the application of a magnetic field and have 
investigated the immune response following the injections of EMHVs 
containing 5-Aza-dC in syngeneic animals and have demonstrated that 
the EMHVs represent a safe and valid drug delivery system that may 
offer numerous advantages for several clinical applications.
Materials and Methods
Preparation of EMHVs
Human and murine erythrocytes were obtained from blood of 
healthy donors by centrifugation at 400 g for 30 min and then washed 
twice in 1X PBS (1.37 M NaCl, 57 mM KCl, 54 mM Na2HPO4, 45 mM 
KH2PO4 pH 7.4). 2x109 erythrocytes were lysed in 250 ml lysis buffer (10 
mM TRIS, 0.1 mM EDTA, 1 mM MgCl2 at pH 7.2) for 60 min at 0°C. The 
isotonicity was then restored by adding 130 ml of resealing buffer (65 
ml of 10 X PBS pH 7.4 and 65 ml of 15 mM MgCl2), supplemented with 
0.1 mg of 100 nm red-labelled superparamagnetic nanoparticles (nano-
screenMAG, Chemicell, Berlin, Germany), 1 mg of hemagglutinin (HA) 
influenza virus glycoprotein, obtained as previously described [20], and 
75 mg of 5-Aza-dC (Sigma-Aldrich, Milan, Italy). The suspension was 
incubated for 45 min at 37°C under mild agitation. EMHVs were then 
collected by centrifugation at 8,000 g for 15 min at 4°C. Successively 
they were washed twice with 1X PBS by centrifugation at 8,000 g for 15 
min at 4°C, resuspended in 1X PBS and conserved at 4°C. 
Samples preparation for HPLC-MS analysis
2x109 of freshly prepared 5-Aza-dC loaded EMHVs were seeded 
in six-wells plates containing 3 ml of RPMI medium, and left at 37°C 
in an atmosphere of 5% CO2 for 24h. Successively, 5-Aza-dC loaded 
EMHVs were collected, lysed and the supernatant containing 5-Aza-
dC was used for HPLC-MS analysis.
HPLC-MS analysis of 5-Aza-dC
HPLC grade acetonitrile, N,N-dimethylhexylamine (DMHA), 
2’-deoxyuridine (dU) and cytidine-5’-triphosphate disodium salt 
(CTP) were purchased from Sigma-Aldrich. Methanol and ammonium 
acetate were obtained from Carlo Erba (Milan, Italy).
2x109 EMHVs containing 5-Aza-dC were lysed in 200 ml of lysis 
buffer for 60 min at 0°C and then centrifuged at 10,000 g for 15 min at 
4°C. The supernatant was transferred into a Microcon centrifugal filter 
device with MWCO 10,000 Da (Amicon YM-10, Millipore, Vimodrone 
MI, Italy) and centrifuged at 14,000 g for 2 hours at 4°C. Filtered 
samples were kept at -80°C until analysis. 170 ng of dU or 400 ng of 
CTP were added to 200 ml of the samples, as internal standards for the 
analysis of the degradation products and of the phosphorylated forms 
of 5-Aza-dC, respectively.
The HPLC system used was a Dionex 3000 Ultimate series LC 
(Sunnyvale, CA, USA) connected to a linear ion trap LTQ-Orbitrap 
mass spectrometer (Thermo Fisher Scientific, USA), equipped with 
an electrospray ion source. Data were acquired and processed with 
Excalibur 2.1 software. 
Compounds were separated on a Mediterranea Sea18 reverse-
phase column (150 mm, 2.1 mm I.D., and 5 mm particle size) from 
Teknokroma (Analytical Technology S.r.l., Brugherio MI, Italy). For all 
the experiments the column was set at a flow rate of 0.25 ml/min, at a 
temperature of 36°C, and sample volumes of 15 ml were injected.
To analyze 5-Aza-dC and its degradation products, the mobile 
phase consisted of 5 mM ammonium acetate (solvent A) and 
acetonitrile (solvent B). The first 13 minutes were an isocratic run 
with solvent A; between 13 and 20 minutes the percentage of mobile 
phase B was increased to 35%, maintained for 2 minutes and then 
the initial the mobile phase was re-established within 2 minutes. The 
mass spectrometer was operated in positive electrospray mode and the 
collision energy was 35 eV. 
To identify the different compounds, the transitions monitored 
were m/z 229--->113 for dU; m/z 229--->113 for 5-Aza-dC; m/z 219-
-->103 for guanylurea derivatives; m/z 247--->131 for formylated 
derivatives. All the transitions were attributable to the cleavage of the 
bond between the nucleobase and the sugar.
5-Aza-dC standard solutions used for the calibration curve were 2, 
4, 6, 8, 10 and 15 mM, all of them containing dU 8 mM. The peak area 
ratio of sample/dU was used for quantization.
To search for possible phosphorylated forms of 5-Aza-dC, the 
mobile phase consisted of 20 mM DMHA pH 7 (solvent A) and 
methanol-water 80:20 (solvent B). The first 12 minutes were an isocratic 
run with 10% solvent B; between 12 and 15 minutes the percentage of 
mobile phase B was increased to 80%, maintained for 1 minute and 
then the initial the mobile phase was re-established within 2 minutes. 
The mass spectrometer was operated in negative electrospray mode and 
the collision energy was 15 eV. 
The transitions monitored were m/z 482--->384 for CTP; m/z 
467--->369 for 5-Aza-dC triphosphate; m/z 387--->289 for 5-Aza-
dC diphosphate; m/z 307--->208 for 5-Aza-dC monophosphate 
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corresponding to the elimination of a neutral molecule of H3PO4.
For the calibration curve, CTP standard solutions 0.1, 0.25, 0.5, 1, 
3 and 6 mM were used. The peak area ratio of sample/CTP was used for 
quantization.
Animals
All the experiments were performed at the Animal Care Facility 
of Marshall University and at the animal facility of the “Toscana Life 
Sciences” foundation.  Both Animal Facilities comply with all necessary 
institutional animal care and biosafety regulations.  
Regarding the animal study conducted at Marshall University, they 
were performed in accordance with NIH recommendations and the 
approval of the institutional animal research committee (MU approval 
#458/2010). Animal care and humane use and treatment of mice were in 
strict compliance with (1) institutional guidelines, (2) the Guide for the 
Care and Use of Laboratory Animals (National Academy of Sciences, 
Washington, DC, 1996), and (3) the Association for Assessment and 
Accreditation of Laboratory Animal Care International (Rockville, 
MD, 1997). All the animals used in the studies conducted at Marshall 
University were 8- to 12-week-old female/male congenitally athymic 
BALB/c nude mice, homozygous for the nu/nu allele, bred in house. 
The colony of the mice was developed from breeding stock obtained 
from Charles Rivers Laboratories, Wilmington, MA. 
Regarding the animal study conducted at the animal facility of the 
“Toscana Life Sciences” foundation, the Italian Minister of Health have 
approved the animal study proposal before becoming an active protocol 
(ISS Protocol approved number CNR-270111 exp 1/prot 3). All 
research involving animals was conducted in full agreement with EU 
legislation and directives (Directive 86/609/EEC of 1986 and Directive 
2010/63/UE) and following the recommendations of local animal ethics 
committees. The experimental design and the experimental procedures 
were customized to avoid or at least to minimize pain, distress and 
other suffering for the animals’ sake (3Rs). Measures to minimize the 
number of animals used were also taken into consideration.
Animals used in the “Toscana Life Sciences” facility were athymic 
nude-foxn1nu and inbred C57BL/6 female mice, 6 weeks of age, which 
were purchased from Harlan Laboratories (Udine, Italy). Animals 
were housed in micro-isolators in the experimental animal facility 
in autoclaved cages with polyester fiber filter covers, under germ-
free conditions.  All food, water, and bedding were sterilized and the 
animals were maintained in an ambient temperature of 23 ± 2°C in 
rooms having a 12 hour light/dark cycle. 
X-ray analysis
Athymic Nude-Foxn1nu mice were injected with EMHVs prepared 
from human donors in the presence or absence of static magnetic field. 
Following tail vein injection of 1.5x108 EMHVs, dissolved in 150 ml of 
PBS, two earth magnets were placed on the lower lateral abdominal 
region for 30 minutes while mice were kept under 2% isofluorane 
anaesthesia.  Magnets were made of neodinium (round shaped 5.0 
mm) and their coercive force was 1000 KOersted, approximately. A 
control group of mice was tail vein injected with EMHVs as previously 
described but without the application of the magnetic field. At the end 
of the treatment course, mice were sacrificed by CO2 asphyxiation and 
the accumulation of ferrous beads was assessed by X-ray imaging. X-ray 
imaging was performed using a Philips DigitalDiagnost direct digital 
radiography system with flat detector technology (Philips, Hamburg, 
Germany) with a dose of 60 kVp at 5 mAs.
Animal treatment for immunological studies
Eight inbred C57BL/6 mice were used as donors of erythrocytes for 
immunological studies. Murine blood was collected from donor mice by 
retro-orbital venous sinus bleeding, while they were under isofluorane 
anesthesia. The donor mice were then sacrificed by CO2 asphyxiation. 
Murine erythrocytes were engineered following the procedure used 
for human EMHVs.  5x108 EMHVs dissolved in 150 ml of PBS were 
tail vein injected in five C57BL/6 host mice, while other five C57BL/6 
untreated mice were used as controls. After 15 days from the injection, 
mice were sacrificed and their blood and spleens were harvested. The 
experiment was repeated three times with similar results.
Isolation of lymphocytes from spleens
Spleen were harvested from mice, immersed in 2 ml of RPMI 
medium in a 3 cm Petri dish and disrupted by scratching them through 
a 70 μm nylon mesh cell strainer (BD Biosciences, Buccinasco, MI) 
with the rubber end of a plunger from a 1 ml syringe. The grid was 
washed with 2 ml of RPMI medium and the cell suspension was then 
transferred in a tube and centrifuged at 300g for 10 min. The pellet 
was resuspended in 500ml RBC Lysis buffer (NH4Cl 155 mM, KHCO3 
10 mM, EDTA 0.1 mM, pH 7.2), gently mixed and then let sit for five 
minutes. The volume was brought up to 4 ml with PBS 1X and left to 
rest at room temperature to decant the membranes for a few minutes. 
The cell suspension was then centrifuged at 300g for 10 min and the 
pellet of cells were used for FACS analysis.
Isolation of lymphocytes and plasma from blood
Bloods collected in heparinized tubes were centrifuged at 400g for 
10 min at 4°C. Each plasma was transferred in a new tube and kept 
at -20°C until analysis. The cell pellet were resuspended in 6 ml of 
RPMI medium and Ficoll density centrifuged at 400g for 30 min. The 
lymphocytes were recovered, washed twice with PBS 1X and then used 
for FACS analysis.
FACS analysis of lymphocytes and Antibodies anti-EMHVs
Subpopulations of peripheral blood and spleen lymphocytes were 
calculated using flow cytometry (Becton-Dikinson BD FACS CantoII). 
The surface markers on lymphocytes were detected by incubation 
with specific monoclonal antibodies against -CD4 (FITC-conjugated), 
-CD8 (APC-conjugated), -CD19 (FITC-conjugated) and -CD154 (PE-
conjugated) (Miltenyi Biotech, Bergisch Gladbach, Germany). 
Lymphocyte samples from both bloods and spleens were divided 
into two groups and used for two different analyses. One group of 
sample was double-stained with anti-CD4 and anti-CD8 antibodies; 
the other group of sample was double-stained with anti-CD19 and 
anti-CD154, following manufacturer’s instructions (Miltenyi Biotech, 
Bergisch Gladbach, Germany). Double-stained samples were then 
analyzed by flow cytometry.
Serum levels of immunoglobulins were detected as follow: plasma 
from each mouse, previously treated with EMHVs, was diluted 1:5, 
1:10, 1:100 and 1:1000 with 1X PBS. 1x108 EMHVs were resuspended 
in 500ml of each dilution and incubated for 1 hour at 4°C. EMHVs were 
washed twice in 1X PBS by centrifugation at 300 g for 5 min at 4°C and 
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blood [23-25]. The main mechanism by which this molecule works 
is the inhibition of the enzyme methyltransferase [26]. However, its 
degradation products are thought to have pharmacological effects that 
may account for the other properties of this drug, such as its toxicity 
[27], its capability to induce the DNA-repair mechanism [28], and its 
suggested mutagenicity [29].
To better characterize 5-Aza-dC encapsulated inside the EMHVs, 
we performed HPLC-MS studies by evaluating the native and intact 
structure of this molecule, but also its principal degradation products. 
In a recent study, the 5-Aza-dC decomposition has been investigated by 
different techniques and the main degradation products were identified 
as formylated and guanylurea derivatives [23]. As a consequence, 
in addition to 5-Aza-dC, we searched also these compounds in our 
EMHVs. To perform this study, 5-Aza-loaded EMHVs were freshly 
prepared and kept at 37°C for 24 hours before HPLC-MS analysis.
Figure 2A shows the results of the HPLC-MS analysis.  The HPLC 
peaks shown represent all the 5-Aza-dC structures found inside freshly 
prepared EMHVs. The four peaks in the top diagram of figure 2A 
identify the guanylurea derivative compounds, which are the a-pentose 
(RT: 2.9), b-pentose (RT: 3.9), a-hexose (RT: 4.5) and b-hexose (RT: 
6.5) isomers. In the diagram in the middle of the same figure are 
evident the peaks of the 5-Aza-dCa- and b-anomers with RT: 5.8 and 
7.4 respectively, and the peak of the internal standard dU (RT: 11.3). 
The peak in the bottom diagram of figure 2A represents the formylated 
derivatives of 5-Aza-dC (RT: 9.5).Figure 2C shows the calibration curve 
we used to quantify all these compounds (see materials and methods 
for more details).
To better understand the fate of 5-Aza-dC loaded inside the 
EMHVs, we analyzed their content following incubation in culture 
medium at the physiological temperature of 37°C for 24-hours.  In these 
conditions, we could not find either the a- and b-anomers of 5-Aza-
dC, or their formylated derivatives. The only compounds detected by 
HPLC-MS analysis were all four of the guanylurea derivatives of 5-Aza-
dC. On the other hand, when we analyzed the free drug, we detected 
the presence of all the structures even after many hours of incubation at 
37°C (data not shown).  To understand the fate of the remaining forms 
of 5-Aza-dC, we performed further analysis.
Since it is known that erythrocytes are complete cells with a simple 
metabolic system, able to act as bioreactors [30-32], we also investigated 
the possibility that enzymes inside the EMHVs could phosphorylate 
the loaded 5-Aza-dC. This molecule, in fact is a pro-drug which 
requires to be activated by a phosphorylation reaction to yield the 
active compound [33].  Because 5-Aza-dC is a nucleoside analogue, it 
needs to be converted to the corresponding 5’-triphosphate nucleotide 
by the cell, before to be incorporated into replicating DNA. For this 
reason, we performed HPLC-MS analysis to verify the presence of 5’-
mono, -di and -triphosphate forms of 5-Aza-dC (5-Aza-dCMP, 5-Aza-
dCDP and 5-Aza-dCTP). Also in this case, we prepared 5-Aza-loaded 
EMHVs and left them at 37°C for 24 hours before proceeding with the 
analysis. 
Figure 2B shows the chromatograms obtained from this study. 
Figure 2B on top shows the chromatogram extracted at m/z = 307, where 
we expected to find the monophosphate form of 5-Aza-dC.  However, 
in the most part of the samples, we did not observe a detectable amount 
of this compound. On the other hand, in the second diagram from 
the top of figure 2B, we can see one peak around 16.6 minutes, which 
reveals the presence of 5-Aza-dCDP.  In the third diagram from the top 
resuspended in 100 ml of 1X PBS. Samples were then incubated with 
FITC-conjugated chicken anti-mouse secondary antibody (Abnova, 
Taiwan) at 1:500 dilution, for 30 min at 4°C. EMHVs were washed twice 
in 1X PBS by centrifugation at 300 g for 5 min at 4°C, resuspended in 
100 ml of 1X PBS and analyzed by flow cytometry.
Results and Discussion
In vivo localization of EMHVs
Magnetic erythrocytes, resulting from the encapsulation of some 
ferrofluids such as cobalt-ferrite and magnetite, have been described 
able to localize to the desired sites under the application of a magnetic 
field [21,22]. To verify if EMHVs can be effectively driven to target 
regions in vivo, athymic nude-Foxn1n mice were treated with human 
EMHVs and exposed or not to static magnetic field. To expose mice to 
the magnetic field, two magnets were applied for 30 minutes in their 
lower lateral abdominal region. We estimated that 30 minutes were 
sufficient to assure repeated passages of the EMHVs near the site of 
interest.  After the treatment, we imaged the mice by X-ray to examine 
the localization of the EMHVs.  Figure 1 shows the radiographs of two 
mice treated with EMHVs in the presence or absence of static magnetic 
field.  In the mice treated with EMHVs and magnets, it is interesting 
to notice a well-defined localized bright spot in the abdomen, which 
corresponds to the site of magnetic application (Figure 1A). On the 
contrary, in the mice treated with EMHVs without the application 
of magnets there is a rather diffuse and homogeneous radiographic 
Figure 1: X-ray image of athymic nude-Foxn1nu mice injected in the tail vein 
with EMHVs in the presence (A) or absence (B) of a static magnetic field. The 
arrow indicates the accumulation of magnetic nanoparticles in a concentrated 
area.
evidence of metal particles throughout all the body (Figure 1B). These 
findings demonstrates that EMHVs can be driven and held at the target 
organ/tissue by means of an external magnetic field and suggest that the 
distribution of this drug delivery system could be controlled because of 
the magnetic properties of nanoparticles encapsulated inside the red 
blood cells. 
Characterization of 5-Aza-dC encapsulated inside the 
EMHVs
It is known that 5-Aza-dC is a quite unstable compound and 
tends to decompose at physiological temperature and pH if free in the 
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is shown that 24 hours from loading the EMHVs, there is the presence 
of triphosphate 5-Aza-dC, as revealed by the appearance of a peak 
around 16.5 minutes.  The bottom diagram of figure 2B shows the peak 
generated by the internal standard CTP (RT: 16.5), that we added to 
our samples as a control. To quantify the amount of the phosphorylated 
forms of 5-Aza-dC, we considered the ratio of sample/CTP. The 
calibration curve has been used to extract this data (Figure 2D). We 
found that 2x109 EMHVs contained about 60 ng of diphosphate 5-Aza-
dC (5-Aza-dCDP) and 85 ng of triphosphate form (5-Aza-dCTP), thus 
confirming that EMHVs can also behave as a bioreactor and activate 
the 5-Aza-dC pro-drug. 
The observation of the presence of phosphorylated forms of 
5-Aza-dC within EMHVs after 24 hours can explain the absence of its 
a- and b-anomers, and of its formylated derivatives. We can suppose 
that deoxycytidine kinases inside EMHVs use both a- and b-5-Aza-
dC as substrates for phosphorylation [34]. As a consequence, if the 
reaction proceeds long enough, the enzyme activity will cause complete 
depletion of these substrates. Furthermore, as the phosphorylation takes 
place, part of 5-Aza-dC starts to decompose giving rise to the above 
mentioned degradation products. However, since the formylated forms 
of 5-Aza-dC are intermediates, which are irreversibly transformed 
into guanylurea derivatives [23], if enough time is available for the 
reaction to take place, then 5-Aza-dC is no more available and all the 
degradation products will be guanylurea derivatives. This can explain 
why, after 24 hours of incubation of the loaded EMHVs at 37 °C, we 
do not find any more a-, b-5-Aza-dC and their formylated derivatives.
The conversion of 5-Aza-dC to phosphorylated 5-Aza-dC (5-Aza-
dCTP) can account for the very high response to the drug that we 
observe when we treat tumor cells with 5-Aza-dC loaded EMHVs in 
vitro [20]. The rapidity of action and efficacy of the drug, in fact, are not 
only due to the ability of EMHVs to release the therapeutic compound 
directly inside the cells, but also to their capacity to phosphorylate the 
compound, so that the released drug is already activated at the time of 
delivery. As a consequence of this, the cells are more responsive to the 
delivered 5-Aza-dC in comparison to cells which are treated with free 
drug, even if at higher doses  [20].
If we consider the 5-Aza-dC and all its derivative compounds that 
we found inside the EMHVs (degradation products and phosphorylated 
forms), we estimated that 2x109 EMHVs accommodated about 120ng 
of total drug. Since during the preparation of the EMHVs we added 
75 mg of 5-Aza-dC, it means that the efficiency of incorporation was 
approximately 3.5%.
Figure 1: X-ray image of athymic nude-Foxn1nu mice injected in the tail vein 
with EMHVs in the presence (A) or absence (B) of a static magnetic field. The 
arrow indicates the accumulation of magnetic nanoparticles in a concentrated 
area.
Figure 2: (A) HPLC-MS chromatograms of 5-Aza-dC and its degradation products. The upper diagram shows the guanylurea derivatives a-pentose (RT: 2.9), b-
pentose (RT: 3.9), a-hexose (RT: 4.5) and b-hexose (RT: 6.5). The diagram in the middle displays thea-and b-anomers of 5-Aza-dC (RT: 5.8 and 7.4, respectively) 
and the internal standard dU (RT: 11.3). The lower diagram shows the formylated derivatives (RT: 9.5). (B) HPLC-MS chromatograms of the phosphorylated forms of 
5-Aza-dC. From top to bottom are displayed the chromatograms for 5-Aza-dC monophosphate (5-Aza-dCMP), diphosphate (5-Aza-dCDP) (RT: 16.6), triphosphate 
(5-Aza-dCTP) (RT: 16.5) and the internal standard CTP (RT: 16.5). (C) Calibration curve reporting the correlation of the peak area ratio between 5-Aza-dC/dU and 
nanograms of 5-Aza-dC. (D) Calibration curve reporting the correlation between the peak area and nanograms of CTP.
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Immunological analysis
Drug delivery systems are currently being used for many therapeutic 
applications. However, some immunological risks could be associated 
with their administration, and with serious clinical implications. Our 
engineered erythrocytes carry a potential immunogenic molecule, the 
HA protein inserted in their membranes, which could potentially cause 
some undesired immune reactions. To gain a deeper understanding 
into the safety of our drug delivery system, we investigated the possible 
immune response induced by the EMHV drug delivery system in mice. 
With this aim in mind, erythrocytes from inbred C57BL/6 mice 
(donors) were engineered as described in material and methods, in 
order to obtain murine EMHVs. Based on the fact that mice have 
about 9x109 erythrocytes per ml of blood and approximately 1.2 ml 
of total blood, 5x108 murine EMHVs were intravenously injected via 
the tail vein into C57BL/6 recipient mice. This amount of engineered 
erythrocytes would be high enough to mount an immune reaction 
in an immunocompetent host and, at the same time, low enough to 
avoid unnecessary pain to the animals caused by an excessive increase 
of their hematocrit. Moreover, the use of inbred C57BL/6 mice both 
as donors of erythrocytes and as recipient of EMHVs allowed us to 
reveal possible immune reactions due exclusively to the HA of the 
vehicle itself.  C57BL/6 mice, in fact, share the same H-2b haplotype 
and consequently no immune response should result from a simple red 
blood cells transfusion between these animals.
After 15 days from the injection, we analyzed the lymphocytes 
subpopulation from both treated and untreated mice in order to assess 
if there were changes in the levels of T and B cells in treated mice, 
in comparison to untreated ones, because of an immune response 
induced by EMHVs infusion. Additionally, we tested for the presence 
of antibodies produced against our delivery system in the plasma of the 
same mice.
The presence of specific receptors on the surface of lymphocytes 
allows distinguishing the different cell types.  T helper cells, in fact, 
which assist other white blood cells in different processes, expose the 
CD4 protein on their surface [35].  Cytotoxic T cells, which defend 
the body against various infections and are responsible for reaction to 
transplants, are also known as CD8+ cells because of the characteristic 
glycoprotein they expose on the surface [35]. When CD4+ T cells 
become activated by specific antigens, they also expose the CD154 
glycoprotein that thus can be used as molecular marker to identify them 
[36]. On the other hand, B lymphocytes, which produce antibodies 
against antigens they get in contact with, are instead characterized by 
the presence of the CD19 protein on their surface [37]. 
Therefore, using the Fluorescence Activated Cell Sorting (FACS) 
Figure 3: (A)Dot plots diagram showing the CD4+ vs. CD8+ and the CD19+ vs. CD154+ profiles of lymphocytes from a representative blood (A) and spleen (B) sample 
of a C57BL/6 mouse which was treated or untreated (ctrl) with EMHVs.  Histograms reporting the different lymphocyte populations from bloods (C) and from spleens 
(D) of untreated (ctrl) and treated C57BL/6 mice.
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method, we studied the status of CD4+, CD8+, CD19+ and CD154+ 
lymphocytes in treated and untreated C57BL/6 mice. 
Figure 3 depicts the representative dot plots showing CD4 vs. CD8 
and CD19 vs. CD154 profiles of the whole lymphocytic populations, 
obtained from the blood (Figure 3A) and the spleens (Figure 3B) 
of treated and untreated C57BL/6 mice. Moreover, the histograms 
in Figure 3C (blood) and 3D (spleen) represent the lymphocytic 
populations found in the blood and spleen of treated and untreated 
C57BL/6 mice, respectively. We observed that the percentages of the 
four different lymphocytic subpopulations were comparable between 
control and treated animals. Furthermore, neither in the controls nor in 
the treated samples we found CD154+ cells, suggesting that no animals 
had activated T lymphocytes and no cell-mediated immune response 
was induced by EMHVs in C57BL/6 mice (Figure 3C and D).
To assess if EMHVs induce early immune response and therefore 
the production of antibodies against our drug delivery system, we also 
analyzed the plasma from treated mice and compared it to control mice. 
EMHVs were incubated with plasma samples at different dilutions. In 
this way, if there were antibodies against our vehicle in the plasma of 
treated mice, they should bind to the EMHVs. Anti-mouse secondary 
antibodies FITC-conjugated were used to detect possible antibodies 
bound to EMHVs by flow cytometry. Figure 4 shows representative 
histograms of the fluorescent signal recorded from these samples. 
More specifically, Figure 4A displays the background fluorescence, 
characteristic of our vehicle, obtained by measuring the signal of 
EMHVs not incubated with plasma and secondary antibodies. On the 
other hand, Figure 4B shows the fluorescence of EMHVs incubated 
with the different plasma samples and secondary FITC-conjugated 
antibody. No changes in the fluorescence intensity has been observed 
in EMHVs exposed (Figure 4B) to plasma of EMHVs injected mice 
respect to control (Figure 4A) suggesting that no antibodies against 
EMHVs were produced by the C57BL/6 treated mice.
Taken together, the results of these preliminary immunological 
studies indicate that neither a cell-mediated nor a humoral immune 
response was induced by our engineered erythrocytes in C57BL/6 
mice. The results suggest that EMHVs are seen as normal homologous 
erythrocytes by the immune system, and consequently, when injected 
in mice having the same haplotype of the donors, they do not cause 
any immune reactions. Our findings suggest that the use of EMHVs 
having the same surface antigens of the red blood cells of the recipient 
(autologous erythrocytes or erythrocytes from individuals having the 
same blood type) could be sufficient to ensure the safety of this drug 
delivery system.
Conclusions
In this work we investigated the effectiveness and safety of EMHVs, 
to gain more knowledge about their use for in vivo applications. We 
observed that these engineered erythrocytes, loaded with magnetic 
nanoparticles are successfully driven at the target region by means of an 
external magnetic field. We also detected that EMHVs can metabolize 
the pro-drug 5-Aza-dC into the active phosphorylated 5-Aza-dC 
(5-Aza-dCTP) suggesting that this drug delivery system is able to deliver 
activated therapeutic molecules to the target cells, which can readily 
use them without the need for further modifications. In addition, we 
observed neither a cell-mediated nor a humoral immune response in 
mice treated with homologous EMHVs, suggesting that although these 
vehicles contain an immunogenic protein (HA) these vehicles have the 
benefit not to elicit an immune response in immunocompetent animals. 
All together these results highlight that EMHVs have many advantages 
that make them potential candidate to be used in the treatment of 
several diseases that require the delivery of therapeutic agents to target 
sites.
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